Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#assertion>. }
Showing items 1 to 10 of
10
with 100 items per page.
- association type Statement assertion.
- association label "farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival see clinical studies 14 1 farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1" assertion.
- association subject drugbank:DB06603 assertion.
- association predicate treats assertion.
- association object DOID_9538 assertion.
- association relation TreatmentIndication assertion.
- drugbank:DB06603 category Drug assertion.
- DOID_9538 category Disease assertion.
- association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- association provided_by NeuroDKG assertion.